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Background. A mobile laboratory transportable on commercial flights was developed to enable local response to viral hemor-
rhagic fever outbreaks.
Methods. The development progressed from use of mobile real-time reverse-transcription polymerase chain reaction to mobile 
real-time recombinase polymerase amplification. In this study, we describe various stages of the mobile laboratory development.
Results. A brief overview of mobile laboratory deployments, which culminated in the first on-site detection of Ebola virus dis-
ease (EVD) in March 2014, and their successful use in a campaign to roll back EVD cases in Conakry in the West Africa Ebola virus 
outbreak are described.
Conclusions. The developed mobile laboratory successfully enabled local teams to perform rapid disgnostic testing for viral 
hemorrhagic fever.
Keywords. Ebola virus disease; laboratory suitcase; mobile laboratory; point of care; viral hemorragic fever virus.
 
Timely viral hemorrhagic fever (VHF) diagnostics in Africa are 
difficult due to distances. Not many specialized laboratories are 
available, and by the time samples reach the National Institute 
for Communicable Diseases (Johannesburg, South Africa) or 
the World Health Organization (WHO) Reference Center for 
Yellow Fever at the Institut Pasteur de Dakar (IPD), they are 
often not fit for use.
Time to result can be very long. Many outbreaks in the past 
decades have shown that the initial lag phase of the outbreaks 
regularly cause infections in healthcare workers. Thus, VHF 
outbreaks amplify and quickly grow out of proportion before 
control measures are initiated, as the recent huge outbreak of 
Ebola virus disease (EVD) in West Africa has shown.
Therefore, the weak link is the lack of mobile onsite diagnos-
tics. Due to the rare occurrence of these diseases (EVD cases: 
2500 [1976–2013], 28 639 [2014–2016]; West Africa [1]), com-
mercial interest is very low, and only a few kits usually confec-
tioned for use in standard laboratories are available [2]. The 
challenge is to take the laboratory into the field for early detec-
tion and response in simple infrastructure settings independent 
of electricity supply and cool chain.
Viral hemorrhagic fevers are infectious febrile diseases that 
can develop into generalized hemorrhages. Manifestations 
are unspecific and show great variability usually with early 
fever, hypotension, bradycardia, tachypnoea, conjunctivitis, 
pharyngitis, and sometimes quite variable exanthema, late 
hemorrhagic diathesis, mucosal or cunjunctival hemorrhages, 
hematuria, hematemesis, melena, intravascular coagulation, 
and shock. Central nervous system manifestations include 
convulsions, delirium, or coma, all of which are predictors 
of mortal outcome [3, 4]. Viruses eliciting these diseases in 
Africa belong to 4, single-strand, ribonucleic acid (RNA) 
virus families: (1) Arenaviridae (Lassa virus [LAV] and Lujo 
virus [LUJV]); (2) Filoviridae (Marburg virus [MARV], Sudan 
virus [SUDV], Ebola virus [EBOV], and Bundibugyo virus 
[BDBV]); (3) Bunyaviridae (Rift Valley fever virus [RVFV] 
and Crimean-Congo hemorrhagic fever virus [CCHFV]); 
(4) Flaviviridae (yellow fever virus [YFV] and dengue virus 
[DENV]). Lujo virus and a new Rhabdovirus, Bas-Congo 
virus (BASV), were only recently described and have not yet 
caused epidemics [5, 6].
With the exception of RVF, dengue fever (DF), and YF, VHF 
can be transmitted by direct contact with blood or body fluids of 
infected patients, facilitating nosocomial infections. Incubation 
times range from 2 to 21  days. Because of the high morbid-
ity and mortality caused by VHF, outbreaks elicit huge media 
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attention driven by the fear of cases exported to industrialized 
countries, which sporadically occur. There is minimal clinical 
and epidemiological knowledge on VHF, and, as the outbreak in 
West Africa showed, the medical infrastructure is bad or almost 
nonexistent, which amplifies these outbreaks.
A general case definition for VHF is severe disease with 
vascular symptoms in a patient who lives or stayed in a VHF-
endemic area or who had contact with live or dead reservoir 
animals (blood, excrements, urine) and/or VHF patients and 
their bodily fluids.
In the field, diagnostic antibody (immunoglobulin [Ig]M, 
IgG) detection assays (enzyme-linked immunosorbent assay 
[ELISA], immunofluorescence assay) developed by special-
ized laboratories need at least a tent laboratory, as recently 
shown in the West African EVD outbreak [7]. Although 
these are not required for diagnosis of acute disease, they are 
important to confirm resolved disease or to monitor disease 
that has progressed beyond the diagnostic window for molec-
ular detection [8].
Virus detection methods include virus isolation or capture 
ELISAs, requiring cell culture or derived antigen preparations 
produced in biosafety level-3 or -4 laboratories, with the excep-
tion of recombinant antigens. Some rapid lateral flow assay 
formats with varying degrees of sensitivity and specificity have 
been described for EBOV detection [9, 10]. The direct detection 
of the virus genome by quantitative real-time reverse-transcrip-
tion polymerase chain reaction qRT-PCR has proven to be suc-
cessful in the large ongoing CCHF epidemic in Turkey and in 
the recent EVD outbreak in West Africa [11–15].
We set out to develop mobile molecular detection for hemor-
rhagic fever viruses (HFVs) with a vision to train a local team 
to deploy and perform VHF diagnostics in outbreak situations. 
The main characteristics of the laboratory were mobility (on 
commercial flights) and independence of electricity and cool 
chain. We describe the development of the mobile laboratory 
(ML) initially using qRT-PCR and later real-time recombinase 
polymerase amplification (RT-RPA) through 4 stages (ML1–4) 
and discuss successful deployments to Cape Verde, Mauritania, 
Uganda, and finally Guinea.
MATERIALS AND METHODS
Mobility
In ML1–2 stages, for qRT-PCR, we chose the SmartCycler 
(Cepheid, Sunnyvale, CA) [16, 17], which was also used by 
other teams [18–21]. In ML3–4a/b stages, for RT-RPA, we used 
the Twista (TwistDx, Cambridge, UK) and the TS2.2 device 
(QIAGEN Lake Constance, Stockach, Germany).
Electricity Supply
In ML1–3, electricity was tapped from a motor vehicle battery 
via inverter (HPL 1200-D-12 inverter, 12V, 1200W). In ML3, 
electricity was tapped via solar panel and power pack Yeti 1250. 
Finally, in ML4, electricity was tapped via solar panel and power 
pack Yeti 400 (GOALZERO, Bluffdale, UT) (Table 1).
Cold Chain Independence
Initially, the QuantiTect Probe RT-PCR Kit (QIAGEN, Hilden, 
Germany) was taken in a cooling bag and kept at 4°C in a refrig-
erator onsite because refrigerators are available in most places, 
even in remote Africa. This kit could be used for up to 2 weeks 
under these conditions, which was usually used up by that time. 
The ML1 used individual primers and probes. The ML2 used 
3 custom-made dried mixes containing primers and probe 
(Roboscreen, Jena, Germany). A 4× screening mix (1 sample, 
1 positive and 1 negative control, 1 volume for pipetting safety, 
and 40 pmol primers/20 pmol probe) was used. The tubes were 
arranged in one box (Figure 1A, box 1) to use them at an out-
break site to identify any of 7 HFVs. The second box contained 
10× mixes (100 pmol primers/50 pmol probe), allowing us to 
test 7 samples, for continuous screening of samples (Figure 1A, 
box 2). The third box contained dried synthetic RNA-positive 
controls, into which 1 volume was transferred from either the 
4× or 10× tube for the positive control reaction (Figure 1A, box 
3). The ML3 was cool chain independent: RT-RPA were reagents 
supplied as dried pellets in 8-strip tubes sealed in aluminium 
foil pouches. The dried primers and probe concept was adapted 
by using 40× tubes (840 pmol of each primer/400 pmol probe 
(TIBMOLBIOL, Berlin, Germany). One 40× stock solution 
resolved in 200 µL water (4.2 µM of each primer/2 µM probe) 
yielded 4 9× master mixes for 8-tube strips by transferring 45 µL 
into each 9× master mix (Figure 2B, Table 2). The ML4 used a 
bespoke TwistAmp exo RT kit (TwistDx, Cambridge, United 
Kingdom) with dried pellets already containing the primers and 
probe. Each pellet contained 21 pmol of each primer and 6 pmol 
probe and MgCl2 (TwistDx, Baraham, United Kingdom [22]).
Amplification
ML1–3 were organized into 5 sites in close proximity 
(Figure  2B–F, [23]). ML4 had only 2 sites (Figure  3A and B 
[24]). Quantitative RT-PCR was performed using published 
primers and probes and RNA standards for RVFV [25], YFV 
[26], EBOV, SUDV, MARV [27, 28], and DENV [29]. For 
CCHFV, the qRT-PCR design was in reference to published 
sequences from African CCHFV isolates (NC_005302, U88410, 
EF123122, U88411, U88415, U88416); for BDBV, primers were 
in reference to sequences FJ217161 and NC_014373 (Table 2). 
Quantitative RNA standards for CCHFV and BDBV were tran-
scribed from the CCHFV-S-segment, and BDBV-N-gene was 
ligated into pCRII and evaluated as previously described [28]. 
The qRT-PCR temperature profile was as follows: room tem-
perature 50°C/5 minutes, activation 95°C/15 minutes, and 45 
cycles of 95°C/5 seconds and 60°C/15 seconds. For CCHFV, the 
same profile was used with a touchdown in 2-degree steps from 
70°C to 64°C for 3 cycles each and 33 cycles at 62°C was used.
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Figure 1. Dried primer and probe mixes. (A) Quantitative reverse transcription-polymerase chain reaction (qPCR) mixes: box 1, 4× screening mix; box 2, 10× PCR mix; box 
3, ribonucleic acid (RNA)-positive controls. Tubes in brown: yellow fever virus (YFV), blue; dengue virus (DENV), red; Crimean-Congo hemorrhagic fever virus (CCHFV), light-
green; Rift Valley fever virus (RVFV), green; Ebola virus (EBOV), pink; Sudan virus (SUDV), orange; Marburg virus (MARV). (B) Real-time recombinase polymerase amplification 
(RT-RPA) 40× mixes (50 per box): box 1, YFV; box 2, DENV1–3; box 3, DENV 4; box 4, Bundibugyo virus (BDBV); box 5, SUDV; box 6, EBOV; box 7, MARV1; box 8, MARV2. (C) 
Results of testing all hemorrhagic fever (VHF) mixes (n = 5) in Kedougou (black circles) and in Dakar (white circles); mean is depicted in red.
A B C
D E F
Figure 2. Mobile laboratory (ML)1–3 pipetting. (A) Field station in Kedougou: (B) site 1, extraction; (C) site 2, master mix; (D) site 3, sample meets mix; (E) site 4, positive 
control meets mix; (F) site 5, amplification devices. The ML3 shown in [23].
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The Sigma virus (SIGV) qRT-PCR (sensitivity, 10 RNA mol-
ecules detected) used for the evaluation of extraction kits was 
performed using the LightCycler 480 RNA Master Hydrolysis 
Probes kit (Roche, Mannheim, Germany) and temperature 
profile: room temperature 63°C/3 minutes, activation 95°C/30 
seconds, and 45 cycles of PCR at 95°C/5 seconds and 53°C/15 
seconds, followed by cooling at 40°C/30 seconds. Real-time RPA 
was performed by using the TwistAmp exo RT kit and dried oli-
gonucleotides as previously described [30]. In ML4, the bespoke 
TwistAmp exo RT kit was used with 45 μL rehydration solution, 
and 5 µL RNA template was added to each pellet containing tube. 
The tubes were mixed, centrifuged, and placed in the Twista for 
A B C
D E F
Figure 3. Mobile laboratory (ML)4 pipetting. (A) Extraction in glovebox. (B) ML4a Real-time recombinase polymerase amplification (RT-RPA) in development of a suitcase 
laboratory (DiaS). (C) The ML4b and 2 RT-RPA in DiaS (Tubescanner II, no laptop). (D) Details of setup for extraction. (E) Opening of internal door of export lock. (F) Export lock 
and waste bag attachment.
Table 1. Mobile Laboratory Components for ML1–4a/b
Mobile Laboratory Items ML1 ML2 ML3 ML4a ML4b
Electricity supply Converter 1 1 1
Solar power pack 1 1 1
Extraction Centrifuge MiniSpin
Rotator Intelli-Mixer Intelli-Mixer
Heating block 1 1
Pipettes 2 1 1 1 1
Amplification Detection device Smart Cycler Smart Cycler Twista Twista TS2.2
Laptop Laptop Laptop Laptop Laptop ----
Centrifuge SC spin down SC spin down Myfuge Spin down Spin down
Lab dancer 1 1 2 2 2
Pipettes 6 5 5 2 2
Energy demand 522W 464W 467W 196W 173W
Biochemistry Extraction QIAGEN Mini Kit QIAGEN Mini Kit/ 
Dynabeads SILANE Viral 
NA
innuPREP MP 
Basic Kit
QIAGEN SpeedXtract 
kit
QIAGEN SpeedXtract 
kit
Oligonucleotides Individual Dried
4× mixes
10× mixes
positive controls
Dried
40× mixes
positive control
Dried
positive control
Dried
positive control
Amplification kit QIAGEN
QuantiTect Probe 
RT-PCR Kit
QIAGEN
QuantiTect Probe RT-PCR 
Kit
Twist
Exo RT-RPA Kit
Twist
Primer-in pellets
Twist
Primer-in pellets
Abbreviations: lab, laboratory; ML, mobile laboratory; RT-PCR, reverse-transcription polymerase chain reaction; RT-RPA, real-time recombinase polymerase amplification.
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real-time monitoring of fluorescence. Reaction was performed 
at 42°C for 20 minutes, as previously described [22].
Extraction
Six commercially available extraction kits were tested in ref-
erence to the QIAGEN QIAamp viral RNA kit ([1] QIAGEN 
QIAamp MinElute Virus Spin; [2] Roche HighPure Viral 
Nucleic Acid; [3] Macherey-Nagel NucleoSpin RNA Virus; 
[4] Invitrogen PureLink Viral RNA/deoxyribonucleic acid 
(DNA) Mini; [5] Invitek RTP DNA/RNA virus Mini; [6] 
Invitrogen Dynabeads SILANE Viral NA). Using Schneider 
S2-cells and concentration of virus culture supernatant through 
ultracentrifugation columns (Amicon Ultra-15; Millipore, 
Darmstadt, Germany), a concentration of 1.7 × 1012/mL SIGV 
RNA molecules was obtained, as confirmed by qRT-PCR.
For the evaluation of the extraction efficiency, 40 μL SIGV stock 
suspension added to 200 µL serum was diluted 1:5 in molecular 
grade H2O, and 140  µL was used for extraction. The required 
sample volume for each kit sample was adjusted with H2O. Each 
extraction was performed in duplicate, and the extracts were 
tested and quantified by qRT-PCR. To simulate field conditions, 
all of the kits, reagents, and materials were held at 36°C for 
1 day, and the experiments were repeated in an incubation room 
at 36°C with a relative humidity of 23%–27%. SpeedXtract kit 
evaluation was described elsewhere [22]. A hard plastic glove-
box consisting of 2 halves, which can be clicked together, was 
purchased from Bodo Könnecke Präzisonsmechanik (Berlin, 
Germany). It features one shunt at the top to enter samples, 1 
double-doored shunt for export of extracts, and 1 shunt to attach 
a double waste bag (Figure 2A and D–F).
RESULTS
Choice of Extraction Kits
Of the 6 commercial extraction kits tested in comparison with 
the QIAGEN QIAamp viral RNA kit, only kit nos. 3 (column 
based) and 6 (magnetic bead based) performed as well as the 
reference kit. We performed an additional assessment of the 
selected extraction methods under field conditions at 37°C 
ambient temperature and 25% humidity. The quantity of recov-
ered nucleic acid was comparable with the default settings at 
25°C (Table  3). Using a magnetic bead stand, the field team 
preferred to use kit no. 6 instead of a centrifuge for extraction. 
For ML4a/b, this extraction method was replaced by the 
SpeedXtract kit (QIAGEN Lake Constance [22]).
Field Trials
In 2010, in a field trial, ML2 was tested in the field laboratory 
of IPD in Kedougou, Senegal (Figure 2A). All dried qRT-PCR 
Table 2. List of RT-PCR and RT-RPA Oligonucleotides
Virus Target Gene Primer and Probe Sequences
qRT-PCR
CCHFV N-gene CCS FP GGYACYAAGAAAATGAAGAAGG
CCS P CTGAGCACHCCAATGAARTGGGG
CCS RP CRGGGAKTGTYCCRAAGCA
BDBV N-gene BDB FP AGGATGGAAACCAAGGCGA
BDB RP TCATGATTTTCGGATCTGTCCTG
BDB P CAACCAATACAGAGACAAGCCAATGCCAC
SIGV G-gene SIG FP GTGACATTCCAAGTAACTGATT
SIG RP CAACGGCAGTTTGGATA
SIG P1 CCCTCCGTGTCCTCCCGGTACC
RT-RPA
BDBV N-gene BDB RPA FP3 AAGCTGAGAAATGGACAGGACCAGGATG
BDB RPA RP1 CTGGACTGTGTTTGAAGGGTTTGGTCATG
BDB RPA P ATCTGTCCTGTACTTGTGGCATTGGCTT-BTF-TCTGTATTGGTTG-P
Degenerated nucleotides in bold (IUB  code).
Abbreviations: BDBV, Bundibugyo virus; BUD RPA-P BTF, B, thymidine nucleotide carrying Blackhole quencher 1; CCHFV, Crimean-Congo hemorrhagic fever virus; F, thymidine nucleotide 
carrying Fluorescein; P, phosphate: 3’phosbate to block elongation; qRT-PCR, quantitative reverse-transcription polymerase chain reaction polymerase chain reaction; RT-RPA, real-time 
recombinase polymerase amplification; SIGV, Sigma virus; T, tetrahydrofuran spacer.
Table 3. Comparative Extraction Efficiency of Final Extraction Kit Selection
Sample Type
Absolute Extraction Result
Efficiency Ratio
(Tested Kit/Reference Kit)
Reference Kit Kit No. 4 Kit No. 7 Kit No. 4 Kit No. 7
SIGV supernatant 1.6 × 108 6.4 × 107 1.4 × 108 0.40 0.9
SIGV spiked serum 9.0 × 107 4.1 × 107 9.2 × 107 0.46 1.0
Abbreviations: SIGV, Sigma virus.
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mixes were tested using the dried RNA standards. Five assays 
for each RNA standard yielded an intra-assay variability from 
0.32 to 0.72 cycle threshold (CT), which was confirmed when 
returning to the laboratory in Dakar (intra-assay variability 
0.28–1.21 CT), and an overall interassay variability from 0.36 to 
1.05 CT (Figure 1C).
Deployments
All deployments of the ML from 2009 to 2014 were upon 
request of the WHO and/or Ministry of Health (MoH) of the 
different countries affected by arbovirus and VHF outbreaks. 
Backup serological diagnostics at IPD used in-house IgM/IgG 
ELISA assays for RVFV, DENV, and YFV. It also provided par-
tial sequencing of DENV E- [31], NS5- [32], and NS5/3-NCR 
[33] regions and of RVFV L, M, and S segments [34].
Dengue Virus 3 Outbreak, 2009, Cape Verde Islands
In October 2009, the WHO Collaborating Centre for Reference 
research on arboviruses of the IPD diagnosed the first DF cases 
from 46 human sera sent by the Division of Epidemiological 
Surveillance, MoH of Cape Verde. The latter, in collabora-
tion with WHO, then invited the IPD to support investiga-
tion, management, and response to the epidemic, and a team 
of entomologists and virologists visited Cape Verde from 
October 26 to November 27, 2009. An in-house IgM/IgG 
ELISA assay, a classic PCR protocol [35] and ML1, were 
deployed at the blood bank of the Hospital Agostinho Neto in 
Praia, to test suspect DF cases. Of 496 sera analysed in total, 1 
cohort of samples (52 of 189; 27%) tested positive by qRT-PCR, 
and another chohort (182 of 399; 46%) tested positive by clas-
sic RT-PCR. Dengue virus was detected on 6 of 10 islands. The 
island of Santiago was the most affected by the DF epidemic with 
213 of 439 positive samples, in comparison to Sal (8 of 19), Fogo 
(3 of 9), Brava (3 of 8), Sao Vicente (2 of 7), and Maio (3 of 6).
Blood bank sera were tested to avoid probable transfusion of 
the virus from asymptomatic blood donors [36]. Twenty-five 
samples tested negative for DENV by qRT-PCR, and 4 of 14 tested 
positive by nested RT-PCR, confirming the importance of the 
analysis of blood products during DF epidemics. Phylogenetic 
analysis of partial sequences of 17 samples determined DENV 
3 in this first DF outbreak in Cape Verde (Ousmane Faye and 
Oumar Faye,  unpublished data), suggesting importation of 
DENV by population movements into and between the island. 
This was confirmed by others [37] and highlighted the need for 
monitoring and research on DF in West Africa.
Rift Valley Fever Outbreak 2010, Mauritania
As part of a collaboration between the National Hospital of 
Nouakchott and the IPD, sera from camels and human cases 
developing hemorrhagic signs were received between November 
and December 2010. Rift Valley fever virus was detected in 6 of 
7 human and 3 of 5 camel samples by qRT-PCR. After a request 
from health authorities, a mission was conducted in Mauritania 
by the IPD from December 8 to 18, 2010 using ML1. A total of 
80 samples were collected by the surveillance and investigation 
teams in Atar, Aoujeft, Akjoujt, Chingetti, Kobeni, and Tintane 
Moughatas, and qRT-PCR scored 22 of 80 (27.5%) sera and 4 
of 85 (4.7%) mosquito pools (2736 mosquitoes) RVFV positive.
At the IPD, 13 sera (59.1%) were positive in IgM-ELISA, and 
virus was isolated from 6 sera (27.2%) by mouse brain inocu-
lation and mosquito cell culture. Virus was isolated from all 4 
RVFV-positive mosquito batches. Phylogenetic analysis of par-
tial L-, S-, and M-segment sequences showed that the strains 
responsible for the outbreak of RVF re-emerged from a local 
RVFV focus, showing the need for continuous surveillance [34].
Yellow Fever Outbreak 2010, Uganda
Laboratory testing conducted by Centers for Disease Control 
and Prevention (CDC)-Fort Collins since November 2010 
confirmed 4 positive cases of YF by PCR and immunohisto-
chemistry in northern Uganda on December 23, 2010. The gov-
ernment of Uganda and WHO/Regional Office of Africa invited 
the IPD to implement virological and entomological investiga-
tions of the YF outbreak and to consult on the control of the 
outbreak. All human sera and mosquito pools (a total of 112 
mosquitoes) collected from affected areas in December 2010 
and January 2011 by the Uganda Virus Research Institute/CDC 
laboratories in Uganda tested negative for YFV and DENV by 
qRT-PCR. In January 2011, 110 serum samples were collected 
from patients in 10 districts (Kitgum [15], Agago [25], Kabong 
[9], Pader [6], Gulu [3], Lamwo [3], Lira [3], Nebbi [2], Yumbe 
[2], Kitgum [1]). Given the insufficient volume of 68 samples, 
only 42 were tested and scored negative for YFV and DENV 
RNA. Additional testing performed in Dakar for IgM antibod-
ies against YFV, DENV, WNV, RVFV, CCHFV, and CHIKV 
revealed the presence of YF IgM in 8 of 42 samples.
Ebola Virus Disease Outbreak in Guinea, 2014–2015
The IPD deployed to Conakry on March 23, 2014. The ML2 using 
qRT-PCR was deployed to the Projet Fièvres Hémorragiques 
Guinée laboratory at the Donka Hospital. The turnaround time 
from sampling to result for suspect cases was approximately 3 
hours. The ML2 used a 3-station workflow [38].
An increasing number of cases, mainly due to nonreporting, 
reticence, and infection transmission chains during burials, 
developed towards the end of 2014. In this context, ML4a/4b 
were deployed to the periphery of Conakry in 2015, to provide 
quick results for the safe and dignified burial (SDB) program. 
They were setup at Matoto Gbessia Port II district at 2 sites. 
Positive results were obtained within 30–40 minutes and 
reported directly to the SDB teams [22].
The ML2 identified (1) the first EVD case in Guinea onsite 
in Conakry on March 23, 2014 and (2) the first cases of EVD in 
Liberia from 2 of 7 EBOV-positive samples collected between 
March 20 and 26, 2014. In total, 1157 of 6055 samples analyzed 
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until May 31, 2015 were EBOV positive. Clinical specimen 
mainly included serum and swabs samples, and the remainder 
consisted of urine, amniotic liquid, and placenta fluid (Faye 
Oumar, Diallo Amadou, Barre Soropogui, Fall Gamou, N'Faly 
Magassouba, Koivogui Lamine, Sakouba Keita, Loucoubar 
Cheikh, Weidmann Manfred, Sall Amadou, and Faye 
Ousmane,  manuscript in preparation). Analysis of the spatial 
distribution of suspected EVD cases revealed confirmation of 
EBOV in 22 of 29 cases managed by SDB teams.
DISCUSSION
The development of an ML for molecular diagnostics of HFV 
lead to the first onsite detection of EBOV in the large EDV out-
break in West Africa in Conakry by a Senegalese team from the 
IPD on March 23, 2014. This report describes the development 
of the ML and its tools used during the large EVD outbreak in 
West Africa in 2014–2015.
For decades, response to outbreaks of VHF relied on deploy-
ment of teams from outside of Africa. This allowed outbreaks 
to gather momentum before onsite investigations began. 
Fortunately, in most cases, the outbreaks happened in remote, 
rural settings, thus naturally curtailing the size of the outbreaks 
due to low population density. However, the EVD outbreak in 
West Africa demonstrated what can happen if a VHF outbreak 
moves into urban settings where population density provides the 
potential for an unlimited reproduction rate (R0) of an epidemic.
In this project, we sought to enable a local team to respond to 
outbreaks and to provide up-to-date molecular diagnostics in an 
equipment setup that allowed rapid transportation on commer-
cial flights. In exercises in 2010 and 2013 in Kedougou, South 
East Senegal and in outbreak field deployments to Mauritania, 
Uganda, and the Cape Verde Islands, the feasibility of the con-
cept was tested. These exercises and deployments helped to 
improve the ML, which progressively used fewer devices and 
pipettes and required less energy moving from qRT-PCT to 
RT-RPA (Table 2).
The molecular assay progressed from using aliquoted PCR 
primers and probes (ML1) to dried primer and probe reac-
tion mixes (PCR [ML2], RPA [ML3]) to RPA primer in pellets 
(ML4). The move from PCR to RPA introduced independence 
from the cooling chain, improved time to result, and led to the 
development of a suitcase laboratory (DiaS), which was success-
fully used during the EVD outbreak in Conakry in 2015 [22, 24]. 
Polymerase amplification in the DiaS has greatly contributed to 
meeting almost all criteria of the ASSURED criteria [39, 40]. 
The sensitivity and specificity of RPA equals that of qRT-PCR 
[22, 41, 42], local teams were trained in the use of ML1-4, 
and ML4 was used by Guinean teams in Conakry. During the 
deployment of ML4a/4b, results were usually provided between 
30 and 40 minutes after receipt of the sample [22].
The ML4a/b setup is of course still not equipment free. An 
ML using a SmartCylers costs approximately $100 000 [20]. One 
fully equipped DiaS costs approximately $9400 and $14 500 with 
the glovebox. Therefore, by meeting most of the requirements 
for improved diagnostic tools set by Global Outbreak Alert and 
Response Network (GOARN) and the WHO Emerging and 
Dangerous Pathogens Laboratory Network (EDPLN) during 
the outbreak [43], ML4a/b has the potential to be used widely 
by African teams as a much more economic option than the 
tent laboratories that were deployed to West Africa from 2014 
to 2015 [7]. Currently, 5 ML4s are based in Senegal, Guinea, 
Egypt, and Sudan.
Costs for qRT-PCR and RT-RPA including extraction 
amounted to $8–$10 per reaction, which is not close to the 
$1 per test target suggested for fieldable point-of-care tests. 
Intensive research and development for molecular diagnostic 
point-of-care tests in the last decade has yielded several con-
cepts that have been brought to market or are close to market 
in industrial countries. The term point-of-care has been used 
profusely, but the various national health systems in Europe 
and their reimbursement modalities only allow use of these 
systems in centralized (high-throughput) laboratories to cover 
rare diagnostic queries or to cover weekend diagnostic needs at 
University hospitals [44]. In addition, selling prices at $120/test 
(FilmArray; BioFire) pose challenges to marketing [45]. During 
the EDV epidemic in West Africa, the GeneExpert system (qRT-
PCR) and the BioFire systems (nested PCR) were evaluated 
[46, 47]. These systems require high investment in devices, and 
prices per reaction are not sustainable outside of international 
funding agencies support. The arrival of the first point-of-care 
devices should be seen as a positive trend; however, affordable 
testing will remain an issue for their development and imple-
mentation. In the face of these current point-of-care test devel-
opments, the DiaS represents a pragmatic approach to taking 
the current state-of-the-art molecular detection assay into the 
field without the need for a laboratory tent concept.
The use of the mobile hard plastic glovebox without negative 
pressure allowed biosafe handling as well as inactivation and 
extraction of viral RNA. A detailed standard operation proce-
dure was developed and successfully used during the deploy-
ment in Guinea. The use of 1% Incidin instead of bleach allowed 
us to avoid problems caused by the corrosive nature of bleach, 
which were previously recorded during the EDV laboratory 
response in West Africa [48].
The future development of this mobile concept will attempt 
to reduce equipment costs even more by adopting simpler 
plastic ware concepts and detection devices or paper detec-
tion formats. The currently existing DiaS has also been 
adopted for detection of arboviruses [30, 49] and Leishmania 
donovani [50].
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CONCLUSIONS
In this study, we have shown that it is possible to reduce the 
amount of equipment and reagents to develop an affordable ML 
concept to take molecular amplification into the field to deliver 
diagnostics in outbreak or surveillance settings.
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